HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 /CNW/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada’s particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF […]
Author Archives: Chris
Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production
New Radioisotope for Cancer Therapy – A new Collaboration to produce Copper-67
SASKATOON, SK, Aug. 25, 2021 /CNW/ – Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies. This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers. (read more)
Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS™ and Solid Targets
BURNABY, British Columbia–(BUSINESS WIRE)–ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development […]
Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS™ and Solid Targets
ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization. The […]
Canadian firms make progress with radioisotope production
Researched and written by World Nuclear News – September 25, 2020 Ontario Power Generation (OPG), its subsidiary Laurentis Energy Partners, BWXT ITG Canada Inc and its affiliates yesterday said they are making “significant progress” towards the production of molybdenum-99 (Mo-99) at OPG’s Darlington plant. Darlington will be the first large-scale nuclear power station to produce […]
CNL Turns Its Attention to Next-Generation of Medical Isotopes
CHALK RIVER, Ontario, Oct. 31, 2019 (GLOBE NEWSWIRE) — Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that it is building on its 70-year history in medical isotope production and research to advance the availability and scientific understanding of actinium-225, a rare medical isotope that has shown great […]
Cyclotron-based gallium-68 generator breaks production records
November 26, 2019 – Gallium-68 (68Ga) is a positron emitter that’s becoming established as a valuable diagnostic isotope, primarily for detection of neuroendocrine tumours (NETs). Such tumours do not metabolize glucose well – precluding their visualization via standard FDG-PET scans – but overexpress somatostatin receptors that bind, for example, to the PET agent 68Ga-Dotatate. Currently, 68Ga is […]
Chuck Conroy Appointed CEO of ARTMS
VANCOUVER, British Columbia-September 10, 2019 -ARTMS Products Inc., the global leader in the innovation and commercialization of novel technologies that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the appointment of Charles S. Conroy R.Ph, MBA as its Chief Executive Officer. Mr. Conroy brings to ARTMS more than 25 […]
ARTMS Products Received $1.5 Million of Funding from the Federal Government
VANCOUVER, British Columbia–August 14, 2019– ARTMS Products Inc., a global leader in the development and commercialization of novel technologies and products that enable cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce they have received $1.5 million funding from Western Economic Diversification Canada as part of its Business Scale-up and Productivity […]
Australian isotope facility to begin full-scale operations
June 13, 2019 – The ANSTO Nuclear Medicine (ANM) facility has received a regulatory licence that will allow it to move to full production of molybdenum-99 (Mo-99), the Australian nuclear science and technology organisation announced today. Limited manufacturing of the isotope began in April after the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) amended […]